davidgoldstein

“Stockpicker’s Paradise”: 2 “Strong Buy” Penny Stocks With Upside Potential Over 200%

“We stick to our view that 2021 will be a stockpicker’s paradise with big money-making opportunities if you are willing to go against the grain,” asserts one small/mid-cap stock strategist cited in today’s article, which proceeds to highlight two penny stocks that boast “Strong Buy” consensus ratings and upside potential over 200%. For these two penny stocks, CLICK HERE.

These 5 Stocks Cost Little And Have “Mammoth Upside Potential”

“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” declares the author of today’s article of the five Buy-rated stocks trading under $10 that he highlights. Among them are a late-stage pharmaceutical company focused on developing potential new therapies for cancer, a security technology company that provides email encryption… 

Which COVID Vaccine Stock Is Best For Which Type Of Investor?

Pfizer, BioNTech, Moderna, Johnson & Johnson, Novavax: Which COVID vaccine stock is the best pick for investors seeking strong growth? What about those looking for income? And how about value investors? The author of today’s article assesses which vaccine stock is best for which type of investor, depending on which factor is the most important to them. For more, CLICK… 

“The Best Proxy For The Trends That Can Help You Make Money”

What’s the best proxy for the trends that can help you make money? The answer may be the 50-day moving average, which the author of today’s article advises “is in the goldilocks zone of not being too short or too long.” Using the example of a potentially game-changing stock from the green energy sector, he outlines how traders can use… 

“The Biggest Contrarian Bet You Can Make Today”

“To me, this is the biggest contrarian bet you can make today. If you’ve got the guts to make the trade, it could lead to massive upside from here,” says the author of today’s article in regards to the investment opportunity he outlines – one that involves an investment that, being cheap, hated and in the start of an uptrend,… 

“Gigantic Upside Potential”: 5 Buy-Rated, Under-$10 Stocks For Aggressive Investors

While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article of the five Buy-rated stocks currently trading under $10 that he proceeds to highlight.… 

4 Tech Stocks To Watch As Investors Go Back To Last Year’s Playbook

With the daily average coronavirus cases being above 150,000 in the U.S., investors have been going back to the old playbook that worked so well last year. This could explain why the tech sector is still performing so well,” notes the author of today’s article before proceeding to highlight four tech stocks in particular to watch this week. For these… 

Better Know These Lesser-Known Biotech Stocks That Have Been Surging

As the biotech sector has received increased investor focus over the past year amid the COVID-19 pandemic, the author of today’s article notes that “Even the smaller and lesser known are being seen now as having immense potential; Many of these companies are working tirelessly toward new drug developments and eyeing larger collaborations.” With that, she proceeds to highlight three… 

5 Buy-Rated Stocks Priced Under $10 Offering Solid Alpha Potential

“While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article in regards to five Buy-rated stocks priced under $10 that he proceeds to highlight.… 

“In A League Of Its Own”: This Immuno-Oncology Stock’s Great Run In 2020 May Have Just Been The Beginning

Trillium Therapeutics surged 1,330% last year – and as an immuno-oncology company, its performance had nothing to do with COVID-19 related catalysts. Moreover, its 2020 run may have just been the beginning, as the company’s cancer-fighting candidates – which it hopes will ultimately replace chemotherapy as the dominant type of cancer treatment – are, as today’s article explains, currently in…